China Resources Biopharma gains Ab Studio's COVID antibody candidate; 3D Medicines, SinoMab, Gloria - News of the day
Elise Mak ·03/16/2022
News


Top news story of the day:

China Resources Biopharma gains Ab Studio's COVID antibody candidate

In a deal without disclosing financial terms, China Resources Biopharma has licensed in U.S. firm Ab Studio's ABS-VIR-001, a trispecific antibody developed as a prophylaxis and therapeutic against SARS-CoV-2 infection.

The Chinese firm will obtain the global development and commercialization rights of the antibody candidate. It will also pay Ab Studio milestone payments and sales-based royalties.

The company did not disclose the plan and timeline for the development of ABS-VIR-001.

Ab Studio wrote in Nature that in preclinical studies, ABS-VIR-001 shows more potent S1 binding, blocking of S1–ACE2 interaction and SARS-CoV-2 neutralization than a combination of individual monoclonal VHH-Fcs.

These data support the idea that ABS-VIR-001 may prove more effective clinically than multi-antibody cocktails, while being simpler to manufacture, and may maintain greater activity versus variants.

In China, regulators have so far approved Pfizer's COVID-19 oral antiviral Paxlovid, as well as Brii Biosciences’ neutralizing monoclonal antibody combination therapy amubarvimab/romlusevimab.

By Elise Mak

What else in China:

China issued the COVID-19 Treatment Protocol (Trial Version 9), which added Pfizer's oral drug and Brii's neutralizing antibody to the treatment drugs, and revised the PCR test threshold to Ct values greater than or equal to 35 for both N and ORF genes.

3D Medicines and Merck announced a collaboration on a clinical trial to evaluate the combination of envafolimab and cetuximab in the treatment of patients with RAS/BRAF wild-type, non-MSI-H/pMMR metastatic colorectal cancer.

SinoMab Bioscience announced that it has received FDA approval for its IND application for the anti-IL-17RB mab SM17 for the treatment of asthma.

Gloria Biosciences submitted a sNDA to the NMPA for a new indication for zimberelimab in cervical cancer.

By Sarina Yang


Keywords: China Resources 3D Medicines SinoMab Gloria
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement